Stockscreener 앱 받기
3.39
2.59%
-0.09
시간 외 거래:
3.49
0.10
+2.95%
전일 마감가:
$3.48
열려 있는:
$3.66
하루 거래량:
353.70K
Relative Volume:
1.57
시가총액:
$129.00M
수익:
-
순이익/손실:
$-27.66M
주가수익비율:
-3.5684
EPS:
-0.95
순현금흐름:
$-24.36M
1주 성능:
-21.89%
1개월 성능:
-26.94%
6개월 성능:
+13.76%
1년 성능:
+33.46%
1일 변동 폭
$3.32
$3.71
1주일 범위
$3.32
$4.9883
52주 변동 폭
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
명칭
Genelux Corp
전화
805-267-9889
주소
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
GNLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.39 | 132.42M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Lake Street | Buy |
| 2024-10-29 | 개시 | Guggenheim | Buy |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-11-27 | 개시 | H.C. Wainwright | Buy |
| 2023-09-12 | 개시 | Maxim Group | Buy |
| 2023-02-15 | 개시 | The Benchmark Company | Speculative Buy |
모두보기
Genelux Corp 주식(GNLX)의 최신 뉴스
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux data update indicates disease early control, says H.C. Wainwright - TipRanks
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com India
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Appoints Veteran Oncologist Jason Litten as CMO - TipRanks
Genelux appoints Jason Litten as CMO - TipRanks
Genelux Corporation Announces Appointment of Jason Litten as Chief Medical Officer, Effective January 2, 2026 - marketscreener.com
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - GlobeNewswire Inc.
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com Nigeria
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Australia
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com Australia
Genelux SVP, Yu Yong, sells shares worth $16k - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
VP Yu Surrenders 4,192 Of Genelux Corp [GNLX] - TradingView — Track All Markets
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Genelux price target raised to $20 from $10 at Maxim - MSN
Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock - MarketBeat
Genelux (GNLX) Stock Analysis Report | Financials & Insights - Benzinga
GENELUX Corp Director Thomas John Sells 10,000 Shares - TradingView
Dir Thomas Sells 10,000 ($50K) Of Genelux Corp [GNLX] - TradingView
Wall Street analysts’ outlook for Genelux Corp (GNLX) - Setenews
Global Retirement Partners LLC Acquires Shares of 228,676 Genelux Corporation $GNLX - MarketBeat
MAI Capital Management Boosts Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux Corporation Executives to Participate in Fireside Chat at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Genelux (NASDAQ: GNLX) sets Dec. 3 fireside chat at Piper Sandler 37th Conference - Stock Titan
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment - MSN
What risks investors should watch in Genelux Corporation stockForecast Cut & Daily Technical Forecast Reports - newser.com
Genelux Corporation's (NASDAQ:GNLX) 16% loss last week hit both individual investors who own 58% as well as institutions - simplywall.st
Genelux initiated with a Buy at Titan Partners - MSN
Combining machine learning predictions for Genelux Corporation2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - newser.com
What momentum indicators show for Genelux Corporation stockSwing Trade & Expert Verified Stock Movement Alerts - newser.com
What valuation multiples suggest for Genelux Corporation stockWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Will Genelux Corporation stock benefit from AI adoptionWeekly Trade Recap & High Return Trade Guides - newser.com
Genelux Corp (GNLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):